Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 4/20 | 0.81 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.81 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.81 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroquinine SCHEMBL109600 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL308963 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinine SCHEMBL109601 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL22754573 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL25429627 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL109603 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL23509584 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL109602 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL25429352 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL22754576 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106908-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | NEUHYLL THERAPEUTICS INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250098680-A1 | A METHOD OF PLANT TREATMENT WITH QUINOLINE ALKALOIDS AND PESTICIDE COMPOSITIONS THEREOF | METABOLIC INSIGHTS LTD. (IL) | 2025-03-27 | — | — | US | claimed |
| CN-119564688-A | Application of quinidine hydride in preparation of medicine for treating migraine | 武汉大学人民医院（湖北省人民医院） | 2025-03-07 | — | — | CN | claimed |
| EP-4465819-A1 | A METHOD OF PLANT TREATMENT WITH QUINOLINE ALKALOIDS AND PESTICIDE COMPOSITIONS THEREOF | Metabolic Insights Ltd. (IL) | 2024-11-27 | — | — | EP | claimed |
| WO-2024150130-A2 | NECROSIS INHIBITOR | LINKGEVITY LIMITED (GB) | 2024-07-18 | — | — | WO | claimed |
| WO-2024141626-A1 | PHARMACEUTICAL FORMULATIONS OF QUINOLINES | TAP PHARMACEUTICALS AG (CH) | 2024-07-04 | — | — | WO | claimed |
| CN-113874341-B | Process for preparing derivatives of 1, 1-dialkylethane-1, 2-diols useful as intermediates | 科学与工业研究委员会 | 2024-05-31 | — | — | CN | claimed |
| WO-2023230770-A1 | METHODS OF LUNG ADENOCARCINOMA TREATMENT WITH NON ANTI-LUAD DRUGS OR COMPOUNDS | Suzhou Singleron Biotechnologies Co., Ltd. (CN) | 2023-12-07 | — | — | WO | claimed |
| EP-0526582-A1 | HETEROCYCLIC CHIRAL LIGANDS AND METHOD FOR CATALYTIC ASYMMETRIC DIHYDROXYLATION OF OLEFINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-02-10 | — | — | EP | claimed |
| WO-1992020677-A1 | HETEROCYCLIC CHIRAL LIGANDS AND METHOD FOR CATALYTIC ASYMMETRIC DIHYDROXYLATION OF OLEFINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-11-26 | — | — | WO | claimed |
| WO-1992014467-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS | DEBIOPHARM S.A. (CH) | 1992-09-03 | — | — | WO | claimed |
| US-5126494-A | Complex osmium catalyst | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-06-30 | — | — | US | claimed |
| WO-1991016322-A2 | HETEROCYCLIC CHIRAL LIGANDS AND METHOD FOR CATALYTIC ASYMMETRIC DIHYDROXYLATION OF OLEFINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-10-31 | — | — | WO | claimed |
| US-4996149-A | Microbiological hydroxylation process of quinine, quinidine and derivatives thereof | NATIVELLE S.A. (FR) | 1991-02-26 | — | — | US | claimed |
| EP-0395729-A1 | LIGAND-ACCELERATED CATALYTIC ASYMMETRIC DIHYDROXYLATION. | MASSACHUSETTS INST TECHNOLOGY (US) | 1990-11-07 | — | — | EP | claimed |
| US-4965364-A | OLEFIN, CHIRAL LIGAND, ORGANIC SOLVENT, WATER, AMINE OXIDE AND OSMIUM-CONTAINING COMPOUND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-10-23 | — | — | US | claimed |
| WO-1989006225-A1 | LIGAND-ACCELERATED CATALYTIC ASYMMETRIC DIHYDROXYLATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-07-13 | — | — | WO | claimed |
| WO-1989005291-A1 | ENANTIOSELECTIVE PREPARATION OF SUBSTITUTED AMINOTHIOPHENOL DERIVATIVES | ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) | 1989-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250098680-A1 | A METHOD OF PLANT TREATMENT WITH QUINOLINE ALKALOIDS AND PESTICIDE COMPOSITIONS THEREOF | DDT, QDPR, KCNQ1 | CYP2D6 1333/4885KDM4E 1407/4885ALDH1A1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.